2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Conditions
Neoplasms
4
Lymphoma, Follicular
4
Lymphoma
4
Infections
4
Neoplasms, Plasma Cell
3
Lymphoma, Non-Hodgkin
3
Leukemia
3
Waldenstrom Macroglobulinemia
2
Thyroid Nodule
2
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neutropenia
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Intraocular Lymphoma
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Febrile Neutropenia
2
Burkitt Lymphoma
2
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Surgical Wound Infection
1
Sepsis
1
Interventions
Meropenem
7
Vancomycin
6
pegfilgrastim
5
Filgrastim
5
Ceftazidime
5
pegylated granulocyte colony-stimulating factor
4
Cefepime
4
Levofloxacin
3
Ciprofloxacin
3
Amikacin
3
Teicoplanin
2
Piperacillin, Tazobactam Drug Combination
2
Linezolid
2
Interleukin 1 Receptor Antagonist Protein
2
Anti-Bacterial Agents
2
Amoxicillin-Potassium Clavulanate Combination
2
ceftolozane, tazobactam drug combination
1
Vaccination
1
Therapeutics
1
Tazobactam
1
TKN732
1
Surveys and Questionnaires
1
Sodium Chloride
1
Simvastatin
1
Positron Emission Tomography Computed Tomography
1
Pneumococcal Vaccines
1
Piperacillin
1
Ofloxacin
1
NF protocol
1
N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Febrile Neutropenia
×
Amoxicillin-Potassium Clavulanate Combination
×
Clear all
NCT05393505
2022-12-06
FRANCiS-NF
The University of Hong Kong
Phase 4
Unknown
344 enrolled
NCT03003273
2019-02-01
DALFEN
All India Institute of Medical Sciences
Phase 3
Terminated
142 enrolled